Supernus Pharmaceuticals (SUPN) Operating Leases (2019 - 2026)

Supernus Pharmaceuticals (SUPN) has 8 years of Operating Leases data on file, last reported at $40.9 million in Q1 2026.

• Operating Leases for Q1 2026 came in at $40.9 million, up 26.62% year-over-year; the trailing twelve-month figure through Mar 2026 was $40.9 million (up 26.62% YoY), and the FY2025 annual result was $41.0 million, up 19.57% from the prior year.
• Operating Leases was little changed at $40.9 million in Q1 2026 per SUPN's latest filing, from $41.0 million in the prior quarter.
• Over five years, Operating Leases peaked at $46.0 million in Q1 2022 and troughed at $24.4 million in Q2 2025.
• A 5-year average of $38.0 million and a median of $40.9 million in 2026 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2022 and 2024: Operating Leases soared 61.33% in 2022, then retreated 25.16% in 2024.
• A 5-year view of Operating Leases shows it stood at $42.8 million in 2022, then dropped by 2.95% to $41.5 million in 2023, then decreased by 17.47% to $34.3 million in 2024, then advanced by 19.57% to $41.0 million in 2025, then retreated by 0.18% to $40.9 million in 2026.
• Business Quant data shows SUPN's Operating Leases at $40.9 million in Q1 2026, $41.0 million in Q4 2025, and $42.2 million in Q3 2025.